Less than one month away from OneMedForumNY 2013, June 26-27 in New York City. We are excited to announce our preliminary presenting company schedule. You can view this list here.

Our Sentinel this week features the second installment of our series on bioinformatics. Bioinformatics has become an essential catalyst to better understanding gene therapy, as well as a unique investment opportunity.

In addition, OneMedRadio spoke with Cyto Wave Therapeutics head George Yu, discussing in vivo testing for CTCs. Lastly, don’t miss our feature exploring the state of influenza, and alternatives to traditional vaccination being developed by NanoViricides (NNVC).

Enjoy this issue.

The effectiveness of Genentech and Roche’s (RHHBY.OB) glioblastoma multiforme (GBM) treatment, Avastin, has recently been challenged raising concerns from physicians and patients alike that a huge void in patient care can develop if the FDA decides to revoke Avastin’s approval for treating GBM.

Or, How I Learned to Stop Worrying and Love Computational Biology.

On May 29th, 2013, GlaxoSmithKline (GSK) announced the acquisition of Okairos in an all-cash deal worth $325 million US. The Okairos acquisition helps complement the pharma giant’s existing vaccine technology and expertise and will enable GSK to continue its work developing the next generation of vaccines.

During an interview with OneMedPlace, President and Chairman of NanoViricides (NNVC) Anil Diwan summed up the influenza treatment market in just a few words: It is like trying to hit a moving target.

Cyto Wave Technologies’ iV3 device can detect circulating tumor cells in real time via laser technology and potentially destroy cells. OneMedRadio spoke with Cyto Wave Technologies President and CEO George Yu about the favorable on-ramp to commercialization, clearing regulatory and reimbursement obstacles and the vast opportunity for in vivo CTC detection.

Healthcare has been one of the hottest sectors over the past year. This can be seen by looking at various ETFs such as iShares Dow Jones US Healthcare (IYH). This particular ETF has appreciated by approximately 35% over the past 52 weeks which is significantly higher than the 27% appreciation that the S&P Depository Receipts (SPY) has given investors. Now the healthcare sector is built up of many smaller industries and this article will focus on medical services companies which have produced strong quarterly results.

OneMedPlac